stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Pharmaron Beijing Co., Ltd.

China · SZSE: 300759.SZ · Market cap: · P/E: · P/S:

Pharmaron is a contract research organization that helps drug companies discover, test, and manufacture new medicines.

Pharmaron is the behind-the-scenes lab partner for the companies that make medicines. When a biotech startup or a giant drugmaker has a promising molecule but neither the space nor the staff to test it properly, they hand the work to Pharmaron. The company runs the experiments, houses the animals, analyzes the blood samples, and figures out whether a compound is safe enough to try in humans.

The business is what the industry calls a contract research organization, or CRO, and the model is simple: customers pay for lab work, and Pharmaron supplies the scientists and equipment. What started as a small chemistry shop in Beijing has grown into a global network with labs and manufacturing sites across China, the United States, and Europe. That footprint matters, because drug development runs around the clock and customers want a partner who can handle a project from early discovery all the way to making pills at commercial scale. The customers are a mix of huge pharmaceutical companies and scrappy venture-backed biotechs, and many of them stay for years because switching labs mid-project is painful and slow. Pharmaron competes with other global CROs and with drugmakers' own in-house labs, but it wins on speed, cost, and the breadth of services under one roof — from chemistry and biology to safety testing and clinical trial support. The company also runs a growing contract manufacturing arm, making active ingredients and finished doses for medicines that are already approved.


China's biotech boom gave Pharmaron a powerful tailwind, and the company has invested heavily in new labs and facilities to capture more of it. Revenue has climbed as global drugmakers outsource more of their research, though the business is exposed to swings in biotech funding and to geopolitical friction between the U.S. and China over drug supply chains. It is a picks-and-shovels play on the drug industry: Pharmaron doesn't need any single medicine to succeed, it just needs the world to keep searching for new ones.

Saved answer · last researched 16 Nov 2026